Hsp90 Regulates a von Hippel Lindau-independent Hypoxia-inducible Factor-1α-degradative Pathway
Open accessThe DOI matches its Crossref record; 80 of the 81 references it cites were found in a registry or an index.
Abstract
HIF-1 alpha is a normally labile proangiogenic transcription factor that is stabilized and activated in hypoxia. Although the von Hippel Lindau (VHL) gene product, the ubiquitin ligase responsible for regulating HIF-1 alpha protein levels, efficiently targets HIF-1 alpha for rapid proteasome-dependent degradation under normoxia, HIF-1 alpha is resistant to the destabilizing effects of VHL under hypoxia. HIF-1 alpha also associates with the molecular chaperone Hsp90. To examine the role of Hsp90 in HIF-1 alpha function, we used renal carcinoma cell (RCC) lines that lack functional VHL and express stable HIF-1 alpha protein under normoxia. Geldanamycin (GA), an Hsp90 antagonist, promoted efficient ubiquitination and proteasome-mediated degradation of HIF-1 alpha in RCC in both normoxia and hypoxia. Furthermore, HIF-1 alpha point mutations that block VHL association did not protect HIF-1 alpha from GA-induced destabilization. Hsp90 antagonists also inhibited HIF-1 alpha transcriptional activity and dramatically reduced both hypoxia-induced accumulation of VEGF mRNA and hypoxia-dependent angiogenic activity. These findings demonstrate that disruption of Hsp90 function 1) promotes HIF-1 alpha degradation via a novel, oxygen-independent E3 ubiquitin ligase and 2) diminishes HIF-1 alpha transcriptional activity. Existence of an Hsp90-dependent pathway for elimination of HIF-1 alpha predicts that Hsp90 antagonists may be hypoxic cell sensitizers and possess antiangiogenic activity in vivo, thus extending the utility of these drugs as therapeutic anticancer agents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, HSP90 inhibitors and histone acetylase inhibitors promote HIFα degradation in a pVHL-independent manner (Isaacs et al., 2002; Kong et al., 2006).”
From Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. (2008) · cites this paper as Isaacs et al., 2002
In the citing paper
“It was reported that inhibitors of Hsp90 such as geldanamycin (GA) could nullify HIF-1α levels regardless of the availability of oxygen42.”
From HIF-1α pathway: role, regulation and intervention for cancer therapy (2015) · cites this paper as [42]
In the citing paper
“GA can induce proteasomal degradation of HIF-1α in a VHL-independent manner both under normoxic and hypoxic conditions (Isaacs et al., 2002).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Isaacs et al., 2002
In the citing paper
“Heat shock protein 90 (HSP90) stabilizes HIF-1α under hypoxia and in tumors, and pharmacological inhibition of HSP90 promotes HIF-1α destabilization [183].”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [183]
Citations
Cites
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
Forsythe, J. A., Jiang, B.-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., & Semenza, G. L. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4604 · Cited by 3,981
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
Semenza, G. L., & Wang, G. L. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.12.5447 · Cited by 2,617
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502
Research works printed but not linked: 18
- Wiesener, 2001, Cancer Res., 61, 5215
- Zhong, 1999, Cancer Res., 59, 5830
- Birner, 2000, Cancer Res., 60, 4693
- Akakura, 2001, Cancer Res., 61, 6548
- Griffiths, 2002, Cancer Res., 62, 688
- Takahashi, 1994, Cancer Res., 54, 4233
- Wizigmann-Voos, 1995, Cancer Res., 55, 1358
- Whitesell, 1992, Cancer Res., 52, 1721
- Shaknovich, 1992, Mol. Cell. Biol., 12, 5059
- Hostein, 2001, Cancer Res., 61, 4003
- Nimmanapalli, 2001, Cancer Res., 61, 1799
- An, 2000, Cell Growth Differ., 11, 355
- Bonvini, 2002, Cancer Res., 62, 1559
- Adams, 1999, Cancer Res., 59, 2615
- Semenza, 1992, Mol. Cell. Biol., 12, 5447
- Hockel, 1999, Cancer Res., 59, 4525
- Mabjeesh, 2002, Cancer Res., 62, 2478
- Kruger, 2001, Clin. Cancer Res., 7, 1867
Cited by
Items 201–300 of 673
Sasabe, E., Zhou, X., Li, D., Oku, N., Yamamoto, T., & Osaki, T. (2007) · International Journal of Cancer · doi:10.1002/ijc.22294 · Cited by 94
KUBOTA, H. Y., Yamamoto, S., Itoh, E., Abe, Y., Nakamura, A., Izumi, Y., Okada, H., Iida, M., Nanjo, H., Itoh, H., et al. (2010) · Cell Stress and Chaperones · doi:10.1007/s12192-010-0211-0 · Cited by 93
Yang, Z. F., Ho, D. W., Lam, C. T., Luk, J. M., Lum, C. T., Yu, W. C., Poon, R. T. P., & Fan, S. T. (2005) · Cancer Research · doi:10.1158/0008-5472.219.65.1 · Cited by 93
“Hsp90 belongs to the chaperone family that plays essential roles in assisting newly synthesized proteins to fold or to translocate through membranes (24), stabilizing protein conformation (25), and helping eliminate denatured proteins (26).”
RetractedHSP90: Enabler of Cancer Adaptation
Jaeger, A. M., & Whitesell, L. J. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055533 · Cited by 99
“Interestingly, HSP90 has been demonstrated to associate with and stabilize HIF1α, suggesting that HSP90 may play an important role in the adaptive response to hypoxia (Isaacs et al. 2002, Nagaraju et al. 2013).”
BackgroundAlderdice, R., Suggett, D. J., Cárdenas, A., Hughes, D. J., Kühl, M., Pernice, M., & Voolstra, C. R. (2020) · Global Change Biology · doi:10.1111/gcb.15436 · Cited by 101
“Heat shock protein 90 (hsp90) also directly interacts with HIFα, acting as a protein stabilizer and induces conformational changes in its structure critical for coupling with HIFβ to form the ‘active HIF complex’ (Gradin et al., 1996; Hur et al., 2002; Isaacs et al., 2002; Katschinski et al., 2004).”
BackgroundHypoxia-inducible factor-1: Regulatory mechanisms and drug development in stroke
Pan, Z., Ma, G., Kong, L., & Du, G. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105742 · Cited by 96
Targeting hypoxia tolerance in cancer
Wouters, B. G., van den Beucken, T., Magagnin, M. G., Lambin, P., & Koumenis, C. (2004) · Drug Resistance Updates · doi:10.1016/j.drup.2003.12.004 · Cited by 96
Ansó, E., Zuazo, A., Irigoyen, M., Urdaci, M. C., Rouzaut, A., & Martínez-Irujo, J. J. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.02.004 · Cited by 92
Harms, K. M., Li, L., & Cunningham, L. A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009767 · Cited by 89
Casein kinase 1 regulates human hypoxia-inducible factor HIF-1
Kalousi, A., Mylonis, I., Politou, A. S., Chachami, G., Paraskeva, E., & Simos, G. (2010) · Journal of Cell Science · doi:10.1242/jcs.068122 · Cited by 88
“RACK1 competes with HSP90 for binding to the HIF-1 N-terminal PAS-A domain.”
BackgroundInfluentialNatural Product-Based Inhibitors of Hypoxia-Inducible Factor-1 (HIF-1)
Nagle, D., & Zhou, Y.-D. (2006) · Current Drug Targets · doi:10.2174/138945006776054979 · Cited by 88
Mahara, S., Lee, P. L., Feng, M., Tergaonkar, V., Chng, W. J., & Yu, Q. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1602079113 · Cited by 87
Bouhamida, E., Morciano, G., Perrone, M., Kahsay, A. E., Della Sala, M., Wieckowski, M. R., Fiorica, F., Pinton, P., Giorgi, C., & Patergnani, S. (2022) · Biology · doi:10.3390/biology11020300 · Cited by 87
Functions of the Per/ARNT/Sim Domains of the Hypoxia-inducible Factor
Yang, J., Zhang, L., Erbel, P. J. A., Gardner, K. H., Ding, K., Garcia, J. A., & Bruick, R. K. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501755200 · Cited by 87
The Hypoxia-Inducible Factor and Tumor Progression Along the Angiogenic Pathway
Brahimi-Horn, M. C., & Pouysségur, J. (2004) · International review of cytology · doi:10.1016/s0074-7696(04)42004-x · Cited by 99
de Candia, P., Solit, D. B., Giri, D. D., Brogi, E., Siegel, P. M., Olshen, A. B., Muller, W. J., Rosen, N. X., & Benezra, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2031337100 · Cited by 86
Lee, S., Jee, J., Bae, J., Liu, K., & Lee, Y. M. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.24813 · Cited by 86
“The presence of active heat shock protein 90 (Hsp90) is also necessary for rapid accumulation and activation of HIF-1a under both hypoxic and nonhypoxic conditions, even without any activity of pVHL (Isaacs et al., 2002).”
BackgroundShenoy, N. K., & Pagliaro, L. C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw241 · Cited by 92
Effects of Histone Deacetylase Inhibitors on HIF-1
Liang, D., Kong, X., & Sang, N. (2006) · Cell Cycle · doi:10.4161/cc.5.21.3409 · Cited by 85
Update on mutations in the HIF: EPO pathway and their role in erythrocytosis
Lappin, T. R. J., & Lee, F. S. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.100590 · Cited by 95
Palayoor, S. T., Tofilon, P. J., & Coleman, C. N. (2003) · PubMed · Cited by 95
Kaluzová, M., Kaluz, S., Lerman, M. I., & Stanbridge, E. J. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.13.5757-5766.2004 · Cited by 83
Hypoxia-inducible factors in OSCC
Pérez‐Sayáns, M., Peñaranda, J. M. S., Pilar, G.-D., Barros, F., Gándara-Rey, J. M., & García, A. G. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.08.017 · Cited by 84
Wartenberg, M., Gronczynska, S., Bekhite, M. M., Saric, T., Niedermeier, W., Hescheler, J., & Sauer, H. (2005) · International Journal of Cancer · doi:10.1002/ijc.20596 · Cited by 82
Contribution of the Type II Chaperonin, TRiC/CCT, to Oncogenesis
Roh, S., Kasembeli, M. M., Bakthavatsalam, D., Chiu, W., & Tweardy, D. J. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161125975 · Cited by 87
“The former include most heat shock proteins (HSPs) whose expression is known to be up regulated in response to environmental stress, most prominently, HSP70 and HSP90.”
BackgroundDefective Tibetan PHD2 Binding to p23 Links High Altitude Adaption to Altered Oxygen Sensing
Song, D., Li, L.-S., Arsenault, P. R., Tan, Q., Bigham, A. W., Heaton-Johnson, K. J., Master, S. R., & Lee, F. S. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.541227 · Cited by 87
Oh, S., Woo, J. K., Jin, Q., Kang, H., Jeong, J., Kim, K., Hong, W. K., & Lee, H. (2008) · International Journal of Cancer · doi:10.1002/ijc.23075 · Cited by 80
Li, F., Luan, W., Zhang, C., Zhang, J., Wang, B., Xie, Y., Li, S., & Xiang, J. (2008) · Cell Stress and Chaperones · doi:10.1007/s12192-008-0069-6 · Cited by 84
“…factor-1α (HIF-1α) and subsequently change the conformation of the heterodimeric complex comprised of HIF-1α and aryl hydrocarbon receptor nuclear translocator to regulate the gene expression for cytoprotection under hypoxia (Ali et al. 1998; Hur et al. 2002; Isaacs et al. 2002, 2004).”
BackgroundHypoxia‐inducible factor‐1 as a therapeutic target in cancer
Tang, C., & Yu, J. Q. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12038 · Cited by 84
Chintala, S., Najrana, T., Toth, K., Cao, S., Durrani, F. A., Pili, R., & Rustum, Y. M. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-293 · Cited by 79
Targeting chaperones in transformed systems – a focus on Hsp90 and cancer
Chiosis, G. (2006) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.10.1.37 · Cited by 79
Jeon, H., Kim, H., Choi, D., Kim, D., Park, S.-Y., Kim, Y.-J., Kim, Y. M., & Jung, Y. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.034041 · Cited by 83
“To test this notion in cells, we transfected an HAHIF-1 and a Flag-VHL plasmid in 293 cells followed by 4-h treatment with a proteasome inhibitor MG-132 in the presence or absence of quercetin.”
BackgroundMethodInfluentialSelf-citationChaperoning Oncogenes: Hsp90 as a Target of Geldanamycin
Neckers, L. (2005) · Handbook of experimental pharmacology · doi:10.1007/3-540-29717-0_11 · Cited by 85
Self-citationThe role of hypoxia-inducible factor-1 alpha in multidrug-resistant breast cancer
Yong, L., Tang, S., Yu, H., Zhang, H., Zhang, Y., Wan, Y., & Cai, F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.964934 · Cited by 91
“Hsp90 inhibitors promoted effective ubiquitination and proteasome-mediated degradation of HIF-1a in RCC under normoxic and hypoxic conditions (53).”
BackgroundImpact of Heat-Shock Protein 90 on Cancer Metastasis
Tsutsumi, S., Beebe, K., & Neckers, L. (2009) · Future Oncology · doi:10.2217/fon.09.30 · Cited by 78
Self-citationTargeting HSP90 as a Novel Therapy for Cancer: Mechanistic Insights and Translational Relevance
Zhang, J., Li, H., Liu, Y., Zhao, K., Wei, S., Sugarman, E. T., Liu, L., & Zhang, G. (2022) · Cells · doi:10.3390/cells11182778 · Cited by 81
“NVP-AUY922, a novel HSP90 inhibitor, promotes HIF1α degradation via VHL E3 ubiquitin ligase [124].”
BackgroundIsaacs, J. S., Jung, Y.-J., & Neckers, L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313342200 · Cited by 76
Self-citationHypoxia-inducible factor in cancer angiogenesis: Structure, regulation and clinical perspectives
Otrock, Z. K., Hatoum, H. A., Awada, A. H., Ishak, R. S., & Shamseddine, A. I. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2009.01.001 · Cited by 87
“[63] Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, Neckers LM.”
BackgroundWang, Z., Wang, D., Han, S., Wang, N., Mo, F., Loo, T. Y., Shen, J., Huang, H., & Chen, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056631 · Cited by 75
An Overview of the Recent Development of Anticancer Agents Targeting the HIF-1 Transcription Factor
Shirai, Y., Chow, C. C. T., Kambe, G., Suwa, T., Kobayashi, M., Takahashi, I., Harada, H., & Nam, J. (2021) · Cancers · doi:10.3390/cancers13112813 · Cited by 79
Transcriptional up‐regulation of FoxM1 in response to hypoxia is mediated by HIF‐1
Xia, L., Huang, W., Wang, B., Liu, M., Zhang, Q., Yan, W., Zhu, Q., Luo, M., Zhou, Z., & Tian, D. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21996 · Cited by 82
“The binding of the von Hippel Lindau tumor suppressor protein (pVHL), resulting in polyubiquitylation and rapid degradation [Isaacs et al., 2002].”
BackgroundLiu, Y., Veena, C. K., Morgan, J. B., Mohammed, K. A., Jekabsons, M. B., Nagle, D. G., & Zhou, Y. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m806744200 · Cited by 77
A TAD Further: Exogenous Control of Gene Activation
Mapp, A. K., & Ansari, A. Z. (2007) · ACS Chemical Biology · doi:10.1021/cb600463w · Cited by 82
Koh, M. Y., Spivak-Kroizman, T. R., & Powis, G. (2009) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-540-78281-0_3 · Cited by 86
Baek, J. H., Liu, Y. V., McDonald, K. R., Wesley, J. B., Zhang, H., & Semenza, G. L. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m705627200 · Cited by 70
Molecular Pathways in Renal Cell Carcinoma—Rationale for Targeted Treatment
KIM, W., & KAELINJR, W. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.06.001 · Cited by 79
Targeting the molecular basis for tumour hypoxia
Carroll, V. A., & Ashcroft, M. A. (2005) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399405009117 · Cited by 108
Xia, M., Ding, Q., Zhang, Z., & Feng, Q. (2016) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-016-0444-2 · Cited by 76
“Existing evidence also suggests that the action of molecular chaperones is required in posttranslational processing of nascent HIF-1a to its mature conformation , especially HSP70 and HSP90 (Isaacs et al. 2002; Minet et al. 1999).”
BackgroundMinoxidil Induction of VEGF Is Mediated by Inhibition of HIF-Prolyl Hydroxylase
Yum, S., Jeong, S., Kim, D., Lee, S., Kim, W., Yoo, J., Kim, J., Kwon, O., Kim, D., Min, D. S., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms19010053 · Cited by 78
Self-citationJones, D. T., & Harris, A. L. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0443 · Cited by 68
HSP90 Inhibitor 17-AAG Selectively Eradicates Lymphoma Stem Cells
Newman, B. W., Liu, Y., Lee, H.-F., Sun, D., & Wang, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3600 · Cited by 71
HSF1: Primary Factor in Molecular Chaperone Expression and a Major Contributor to Cancer Morbidity
Prince, T. L., Lang, B. J., Guerrero-Gimenez, M. E., Fernandez-Muñoz, J. M., Ackerman, A., & Calderwood, S. K. (2020) · Cells · doi:10.3390/cells9041046 · Cited by 70
Li, T., & Brouwer, M. H. (2007) · Comparative Biochemistry and Physiology Part B Biochemistry and Molecular Biology · doi:10.1016/j.cbpb.2006.12.018 · Cited by 68
“This domain forms a secondary dimerization interface between family members in addition to other roles, such as ligand and chaperone binding in the dioxin receptor (DR) ( Isaacs et al., 2002 ).”
BackgroundSEPT9_v1 Up-regulates Hypoxia-inducible Factor 1 by Preventing Its RACK1-mediated Degradation
Amir, S., Wang, R., Simons, J. W., & Mabjeesh, N. J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808348200 · Cited by 76
Malik, B., Nirmalananthan, N., Gray, A., Spada, A. L., Hanna, M., & Greensmith, L. (2013) · Brain : a journal of neurology · doi:10.1093/brain/aws343 · Cited by 77
Beneficial and Detrimental Roles of Heme Oxygenase-1 in the Neurovascular System
Choi, Y. K., & Kim, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137041 · Cited by 67
Roles for HIF-1α in neural stem cell function and the regenerative response to stroke
Cunningham, L. A., Candelario, K. M., & Li, L. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.08.002 · Cited by 71
CTP synthase forms the cytoophidium in human hepatocellular carcinoma
Chang, C., Jeng, Y., Peng, M., Keppeke, G. D., Sung, L., & Liu, J. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.10.030 · Cited by 65
Wawrzynów, B., Żylicz, M., & Żylicz, M. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.12.004 · Cited by 67
Hypoxia: syndicating triple negative breast cancer against various therapeutic regimens
Srivastava, N., Usmani, S. S., Subbarayan, R., Saini, R., & Pandey, P. K. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1199105 · Cited by 72
Hypoxia-inducible factor 1 contributes to N-acetylcysteine’s protection in stroke
Zhang, Z., Yan, J., Taheri, S., Liu, K. J., & Shi, H. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.11.007 · Cited by 71
The Double-Edged Sword: Conserved Functions of Extracellular Hsp90 in Wound Healing and Cancer
Hance, M. W., Nolan, K. D., & Isaacs, J. S. (2014) · Cancers · doi:10.3390/cancers6021065 · Cited by 66
“clients [6], many of which are implicated in malignancy [7–11], nuclear clients have also been characterized [12,13].”
BackgroundSelf-citationHsp90 as a Gatekeeper of Tumor Angiogenesis: Clinical Promise and Potential Pitfalls
Bohonowych, J. E., Gopal, U., & Isaacs, J. S. (2010) · Journal of Oncology · doi:10.1155/2010/412985 · Cited by 63
Self-citationUbiquitin Ligase RLIM Modulates Telomere Length Homeostasis through a Proteolysis of TRF1
Her, Y. R., & Chung, I. K. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m806702200 · Cited by 73
“These data indicate that hTERT is ubiquitinated in GAtreated cells prior to proteasome-dependent degradation in a manner similar to other Hsp90 client proteins ( Isaacs et al. 2002 ).”
BackgroundResultEffects of curcumin on hypoxia-inducible factor as a new therapeutic target
Bahrami, A., Atkin, S. L., Majeed, M. A., & Sahebkar, A. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.10.009 · Cited by 67
Li, Z., You, Q., & Zhang, X. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01596 · Cited by 65
Kubo, T., Maezawa, N., Osada, M., Katsumura, S., Funae, Y., & Imaoka, S. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.04.125 · Cited by 63
Yang, Z. F., Poon, R. T. P., To, J. Y., Ho, D. W., & Fan, S. T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3311 · Cited by 66
RetractedHe, Y., Chang, Q., & Lu, F. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100687 · Cited by 82
“The authors speculated that HBOT activated the Hsp90 protein by increasing ROS generation, stabilizing HIF-1 and protecting it from degradation [35].”
BackgroundHubert, A., Paris, S., Piret, J.-P., Ninane, N., Raes, M., & Michiels, C. (2006) · Journal of Cell Science · doi:10.1242/jcs.03069 · Cited by 62
“Jo ur na l o f C el l S ci en ce 3357CK2 activates HIF-1 by p53 downregulation association with Hsp90 (Isaacs et al., 2002; Minet et al., 1999), phosphorylation (Minet et al., 2000; Mottet et al., 2003; Richard et al., 1999), sequestration in the nucleolus by p14ARF (Fatyol and Szalay, 2001) as…”
BackgroundSadri, N., & Zhang, P. J. (2013) · Cancers · doi:10.3390/cancers5020320 · Cited by 67
“HIF1α protein stability can be targeted by 17DMAG, an inhibitor of the chaperone heat sock protein 90 (Hsp90) [74].”
BackgroundVlaminck, B., Toffoli, S., Ghislain, B., Demazy, C., Raes, M., & Michiels, C. (2007) · The FEBS Journal · doi:10.1111/j.1742-4658.2007.06072.x · Cited by 61
Yang, Y., Ji, C., Zhi-gang, B., Lu, C., Wang, R., Gu, B., & Cheng, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054736 · Cited by 62
Zhou, Z., Liu, F., Zhang, Z.-S., Shu, F., Zheng, Y., Fu, L., & Li, L.-Y. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1027 · Cited by 69
Understanding the Oxygen-Sensing Pathway and Its Therapeutic Implications in Diseases
Liao, C., & Zhang, Q. H. (2020) · American Journal Of Pathology · doi:10.1016/j.ajpath.2020.04.003 · Cited by 67
Koga, F., Tsutsumi, S., & Neckers, L. M. (2007) · Cell Cycle · doi:10.4161/cc.6.11.4296 · Cited by 61
Self-citationTargeting HSF1 sensitizes cancer cells to HSP90 inhibition
Chen, Y., Chen, J., Loo, A. T., Jaeger, S. A., Bagdasarian, L., Yu, J., Chung, F. S., Korn, J. M., Ruddy, D. A., Guo, R., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.991 · Cited by 66
Murtagh, J., Lu, H., & Schwartz, E. L. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0748 · Cited by 66
Mo, Y., Zhang, Y., Zhang, Y., Yuan, J., Mo, L., & Zhang, Q. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01117-7 · Cited by 64
van der Bilt, J. D. W., Soeters, M. E., Duyverman, A. M. M. J., Nijkamp, M. W., Witteveen, P. O., van Diest, P. J., Kranenburg, O., & Rinkes, I. H. M. B. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.061028 · Cited by 61
Wu (2011) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2011.600 · Cited by 59
Song, D., Li, L.-S., Heaton-Johnson, K. J., Arsenault, P. R., Master, S. R., & Lee, F. S. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.440552 · Cited by 61
“This model is compatible with previous observations that HIF-1 is itself an HSP90 client protein (24) and also with previous work which indicates that p23 enters the HSP90 cycle at a late stage in the maturation cycle of HSP90 client proteins (23).”
BackgroundResultInfluentialClinical implications of hypoxia inducible factor in renal cell carcinoma
Smaldone, M. C., & Maranchie, J. K. (2009) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2007.12.001 · Cited by 65
Kalinowski, L., Janaszak-Jasiecka, A., Siekierzycka, A., Bartoszewska, S., Woźniak, M., Lejnowski, D., Collawn, J. F., & Bartoszewski, R. (2016) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-016-0017-x · Cited by 58
Impact of Carcinogenic Chromium on the Cellular Response to Proteotoxic Stress
Ferreira, L. M. R., Cunha‐Oliveira, T., Sobral, M. C. M., Abreu, P. L., Alpoim, M. C., & Urbano, A. M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194901 · Cited by 66
Comparative Biology of Oxygen Sensing in Plants and Animals
Holdsworth, M. J., & Gibbs, D. J. (2020) · Current Biology · doi:10.1016/j.cub.2020.03.021 · Cited by 59
HSP90 Supports Tumor Growth and Angiogenesis through PRKD2 Protein Stabilization
Azoitei, N., Diepold, K., Brunner, C., ROUHI, A. M., Genze, F., Becher, A., Kestler, H. A., Lint, J. V., Chiosis, G., Koren, J., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1017 · Cited by 60
Inhibition of Hypoxia-Inducible Factor-1α (HIF-1α) Protein Synthesis by DNA Damage Inducing Agents
Lou, J. J. W., Chua, Y. L., Chew, E. H., Gao, J., Bushell, M., & Hagen, T. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010522 · Cited by 57
Chen, R., Liliental, J., Kowalski, P., Lu, Q., & Cohen, S. N. (2011) · Oncogene · doi:10.1038/onc.2010.623 · Cited by 60
“Upregulation of HIF-1a expression or blockade of the degradation can also occur under normoxic conditions in cancer cells, contributing to tumor progression (Jiang et al., 1997; Isaacs et al., 2002; Chi and Karliner, 2004; Busca et al., 2005).”
BackgroundPrince, T. L., Kijima, T., Tatokoro, M., Lee, S., Tsutsumi, S., Yim, K. H., Rivas, C., Alarcon, S. V., Schwartz, H., Khamit-Kush, K. K., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141786 · Cited by 60
Self-citationHypoxia-regulated gene network in drug resistance and cancer progression
Lin, S.-C., Liao, W.-L., Lee, J., & Tsai, S. (2014) · Experimental Biology and Medicine · doi:10.1177/1535370214532755 · Cited by 61
COMMD1 Promotes pVHL and O2-Independent Proteolysis of HIF-1α via HSP90/70
van de Sluis, B., Groot, A. J., Vermeulen, J., van der Wall, E., van Diest, P. J., Wijmenga, C., Klomp, L. W., & Vooijs, M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007332 · Cited by 56
Zhang, C., Liu, Q., Li, M., Lin, S., Peng, Y., Wu, D., Li, T. Y., Fu, Q., Jia, W., Wang, X., et al. (2015) · Cell Research · doi:10.1038/cr.2015.90 · Cited by 60
PTEN suppression of YY1 induces HIF-2 activity in von hippel lindau null renal cell carcinoma
Petrella, B. L., & Brinckerhoff, C. E. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.14.8880 · Cited by 55
Liu, L., Mao, L., Wu, X., Wu, T., Liu, W., Yang, Y., Zhang, T., & Xu, Y. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.06.015 · Cited by 57
Gao, W., Ferguson, G., Connell, P., Walshe, T. E., Murphy, R. P., Birney, Y. A., O'Brien, C. J., & Cahill, P. A. (2006) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2006.12.006 · Cited by 55
Ikeda, H., & Kakeya, H. (2021) · The Journal of Antibiotics · doi:10.1038/s41429-021-00451-0 · Cited by 65
Management of von Hippel–Lindau-associated kidney cancer
Grubb, R. L., Choyke, P. L., Pinto, P. A., Linehan, W. M., & Walther, M. M. (2005) · Nature Clinical Practice Urology · doi:10.1038/ncpuro0179 · Cited by 52
Genetics of pheochromocytoma and paraganglioma syndromes: new advances and future treatment options
Vícha, A., Musil, Z., & Pacák, K. (2013) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32835fcc45 · Cited by 59
Unusual Suspects in the Twilight Zone Between the Hsp90 Interactome and Carcinogenesis
Vartholomaiou, E., Echeverría, P. C., & Picard, D. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2015.08.001 · Cited by 61
Metadata
- Authors
- Isaacs, J. S., Jung, Y.-J., Mimnaugh, E. G., Martinez, A., Cuttitta, F., & Neckers, L. M.
- Affiliations
- National Institutes of Health (US)
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2002-08
- Volume
- 277
- Issue
- 33
- Pages
- 29936-29944
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2022471909
- Cited by
- 663
- References
- 81
- Citations by year
- 2026: 13 · 2025: 12 · 2024: 10 · 2023: 19 · 2022: 22 · 2021: 32 · 2020: 19 · 2019: 20 · 2018: 19 · 2017: 20 · 2016: 22 · 2015: 30 · 2014: 31 · 2013: 27 · 2012: 41
- FWCI
- 13.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6667 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- HSP90, HIF-1α, VHL, hypoxia, protein degradation, geldanamycin, E3 ubiquitin ligase, proteasome, renal carcinoma, angiogenesis, vascular endothelial growth factor, anti-angiogenic therapy, hypoxic cell radiosensitizers
- MeSH terms
- Cysteine Endopeptidases, Hydrolysis, Ligases, Multienzyme Complexes, Transcription Factors, Transcription, Genetic, Tumor Cells, Cultured, Down-Regulation, HSP90 Heat-Shock Proteins, Tumor Suppressor Proteins, Ubiquitin-Protein Ligases, Proteasome Endopeptidase Complex, Von Hippel-Lindau Tumor Suppressor Protein, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.